AMPH

#2495
Amphastar Pharmaceuticals, Inc. - Common Stock
22.0 1 USD
+0.01%
Market Price
Settore: Salute
Base: USD
Valuta di Profitto: USD
Intervallo Giornaliero
22.01
22.01
Intervallo Annuale
16.65
29.52
Variazione giornaliera
+0.59%
Variazione Mensile
+8.16%
Variazione di 6 mesi
+8.42%
Variazione Annuale
-9.72%
Chiusura Precedente
21.8 8
Open
22.0 1
Minimo
22.0 1
Massimo
22.0 1
Volume
59
Apri il grafico completo

Financials

Panoramica Estratto Conto Statistiche Documents

2026

Current report, Q3 FY2026
Amphastar Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Amphastar Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Current report, Q3 FY2026
Amphastar Pharmaceuticals, Inc. current report, Q3 FY2026
8-K
Quarterly report, Q2 FY2026
Amphastar Pharmaceuticals, Inc. quarterly report, Q2 FY2026
10-Q
Current report, Q2 FY2026
Amphastar Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Current report, Q2 FY2026
Amphastar Pharmaceuticals, Inc. current report, Q2 FY2026
8-K
Quarterly report, Q1 FY2026
Amphastar Pharmaceuticals, Inc. quarterly report, Q1 FY2026
10-Q
Current report, Q1 FY2026
Amphastar Pharmaceuticals, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Amphastar Pharmaceuticals, Inc. current report, Q1 FY2026
8-K
Current report, Q1 FY2026
Amphastar Pharmaceuticals, Inc. current report, Q1 FY2026
8-K

Amphastar Pharmaceuticals, Inc. current report, 13 April 2020

Full document

Business Context and Reporting Period

This Form 8-K Current Report was filed by Amphastar Pharmaceuticals, Inc. on April 13, 2020. The filing reports a material change in corporate governance and executive leadership effective immediately on the date of the report.

Key Financial Metrics

The filing does not provide standard financial performance metrics such as revenue, profit, cash flow, margins, debt, or liquidity. The only financial data disclosed relates to the compensation package for a departing executive.

Material Changes

  • Executive Departure: Jason B. Shandell resigned as President, General Counsel, and Board member. The resignation was mutual and not the result of any disagreement regarding operations, policies, or practices.
  • Leadership Appointment: Dr. Jack Y. Zhang, the Company's CEO and Chief Scientific Officer, assumed the role of President effective immediately. No changes were made to Dr. Zhang's existing compensatory arrangements.
  • Separation Agreement: A separation agreement was executed with Mr. Shandell, including a cash payment of $2,425,376, vesting of 80% of unvested options and RSUs, a buyout of his interest in Amphastar Nanjing Pharmaceuticals Inc. at fair market value, and three years of healthcare coverage.

Guidance, Outlook, and Risks

The filing contains no financial guidance, outlook, or management commentary regarding future business performance. The primary risk disclosed is the transition of executive leadership, though the Company explicitly states the departure was amicable. The full Separation Agreement will be filed as an exhibit to the Form 10-Q for the quarter ending June 30, 2020.

Investor Verification Checklist

  • Verify the impact of the leadership transition on the Company's strategic direction and operational continuity.
  • Review the full Separation Agreement (to be filed in the Q2 2020 10-Q) for details on the buyout of the Amphastar Nanjing Pharmaceuticals Inc. interest.
  • Confirm that no other undisclosed disagreements or legal contingencies exist regarding Mr. Shandell's departure.

Notizie